Insmed stock price target raised to $223 by TD Cowen on strong Brinsupri launch
PositiveFinancial Markets

TD Cowen has raised the stock price target for Insmed to $223, driven by the strong launch of its new drug, Brinsupri. This positive adjustment reflects confidence in the company's growth potential and the drug's market performance, which could lead to increased investor interest and a boost in stock value.
— Curated by the World Pulse Now AI Editorial System